Literature DB >> 8753786

Synergistic induction of nitric oxide by beta-amyloid and cytokines in astrocytes.

F Rossi1, E Bianchini.   

Abstract

The deposition of beta-amyloid peptides in the brain in form of senile plaque is the key event responsible for Alzheimer pathology. Among various mechanisms that have been proposed to explain the neurotoxicity of beta-amyloid deposits, a new one, recently identified in our laboratory, suggests that beta-amyloid peptides may be indirectly toxic for neurons by activating microglial cells to produce NO (2). We have investigated if astrocytes, nerve cells that play an important role in many brain diseases, also might be involved in a similar mechanism of neuronal damage. The results have demonstrated that (1) beta-amyloid peptide (25-35), in the presence of IFN gamma or TNF alpha, induces the production of NO in the astrocyte cell line C6, while neither cytokine was effective per se; (2) NO generation is also synergically induced by beta-amyloid peptide (25-35) in the presence of IL-1 beta, the latter being a cytokine able to activate astrocytes per se; (3) the effect of beta-amyloid peptide (25-35) is due to the induction of the expression of the gene of inducible NO-synthase. These findings suggest that astrocytes, activated by deposited beta-amyloid peptides and cytokines, may play a role in neuronal damage via the indirect NO mechanism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8753786     DOI: 10.1006/bbrc.1996.1197

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

Review 1.  The role of inflammasome in Alzheimer's disease.

Authors:  Li Liu; Christina Chan
Journal:  Ageing Res Rev       Date:  2014-02-19       Impact factor: 10.895

Review 2.  The role of nitric oxide in neurodegeneration. Potential for pharmacological intervention.

Authors:  J A Molina; F J Jiménez-Jiménez; M Ortí-Pareja; J A Navarro
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

3.  Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism.

Authors:  K T Akama; C Albanese; R G Pestell; L J Van Eldik
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

4.  Angiotensin converting enzyme and endothelial nitric oxide synthase DNA polymorphisms and late onset Alzheimer's disease.

Authors:  R Alvarez; V Alvarez; C H Lahoz; C Martínez; J Peña; J M Sánchez; L M Guisasola; J Salas-Puig; G Morís; J A Vidal; R Ribacoba; B B Menes; D Uría; E Coto
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

5.  Aβ potentiates inflammatory activation of glial cells induced by scavenger receptor ligands and inflammatory mediators in culture.

Authors:  P Murgas; B Godoy; R von Bernhardi
Journal:  Neurotox Res       Date:  2012-01-12       Impact factor: 3.911

6.  Increased vulnerability of neuronal cell lines to sodium nitroprusside-mediated toxicity is caused by the decreased level of nitric oxide metabolites.

Authors:  C Ghosh; D K Lahiri
Journal:  J Mol Neurosci       Date:  1999 Aug-Oct       Impact factor: 3.444

Review 7.  Neuroinflammatory processes in Alzheimer's disease.

Authors:  Michael T Heneka; M Kerry O'Banion; Dick Terwel; Markus Peter Kummer
Journal:  J Neural Transm (Vienna)       Date:  2010-07-15       Impact factor: 3.575

Review 8.  Battling Alzheimer's Disease: Targeting SUMOylation-Mediated Pathways.

Authors:  Wagner Carbolin Martins; Carla Inês Tasca; Helena Cimarosti
Journal:  Neurochem Res       Date:  2015-07-31       Impact factor: 3.996

9.  Effects of Gengnianchun on learning and memory ability, neurotransmitter, cytokines, and leptin in ovariectomized rats.

Authors:  Yan-Qiu Rao; Jun Li; Wen-Jun Wang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

10.  Pharmacological characterization of novel A3 adenosine receptor-selective antagonists.

Authors:  K A Jacobson; K S Park; J L Jiang; Y C Kim; M E Olah; G L Stiles; X D Ji
Journal:  Neuropharmacology       Date:  1997-09       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.